{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:30:31Z","timestamp":1793093431897,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Center for Emerging Technologies Governance in Medicine and Public Health"},{"name":"National Natural Science Foundation of China","award":["72174041"],"award-info":[{"award-number":["72174041"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-15065-1","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:33:51Z","timestamp":1783341231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug price trends, regional disparities, and supply shortages under China\u2019s National Volume-Based Procurement: a nationwide analysis (2018\u20132024)"],"prefix":"10.1186","volume":"26","author":[{"given":"Biao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"Suppl 2","key":"15065_CR1","first-page":"2","volume":"14","author":"GM Leung","year":"2008","unstructured":"Leung GM, Tin KY, Yeung GM, Leung ES, Tsui EL, Lam DW, et al. Hong Kong\u2019s domestic health spending\u2013financial years 1989\/90 through 2004\/05. Hong Kong Med J. 2008;14(Suppl 2):2\u201323.","journal-title":"HONG KONG MED J"},{"issue":"14","key":"15065_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ajhp\/zxad086","volume":"80","author":"EM Tichy","year":"2023","unstructured":"Tichy EM, Hoffman JM, Tadrous M, Rim MH, Suda KJ, Cuellar S, et al. National trends in prescription drug expenditures and projections for 2023. Am J Health-Syst Ph. 2023;80(14):899\u2013913.","journal-title":"AM J HEALTH-SYST PH"},{"key":"15065_CR3","unstructured":"Spherical insights: global pharmaceutical market report coverage. 2025. Available from: https:\/\/www.sphericalinsights.com\/reports\/pharmaceutical-market."},{"key":"15065_CR4","unstructured":"Spherical insights: China pharmaceuticals market report coverage. 2025. Available from: https:\/\/www.sphericalinsights.com\/reports\/china-pharmaceuticals-market."},{"key":"15065_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.socscimed.2018.11.029","volume":"220","author":"OJ Wouters","year":"2019","unstructured":"Wouters OJ, Sandberg DM, Pillay A, Kanavos PG. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Soc Sci Med. 2019;220:362\u201370.","journal-title":"SOC SCI MED"},{"issue":"5","key":"15065_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.healthpol.2016.03.014","volume":"120","author":"J Hu","year":"2016","unstructured":"Hu J, Mossialos E. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Health Policy. 2016;120(5):519\u201334.","journal-title":"Health Policy"},{"key":"15065_CR7","unstructured":"Organisation for Economic Cooperation and Development\/World Health Organization. Health at a Glance: Asia\/Pacific 2018: Measuring Progress towards Universal Health Coverage. In OECD Publishing|.*OECD Publishing*OECD Publishing. Paris; 2018."},{"issue":"14","key":"15065_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ajhp\/zxaf092","volume":"82","author":"EM Tichy","year":"2025","unstructured":"Tichy EM, Rim MH, Cuellar S, Tadrous M, Schumock GT, Johnson TJ, et al. National trends in prescription drug expenditures and projections for 2025. Am J Health-Syst Ph. 2025;82(14):806\u201321.","journal-title":"AM J HEALTH-SYST PH"},{"key":"15065_CR9","doi-asserted-by":"crossref","unstructured":"Zhu Z, Wang Q, Sun Q, Lexchin J, Yang L. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Glob Health. 2023;8(7).","DOI":"10.1136\/bmjgh-2022-011535"},{"issue":"3","key":"15065_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/23812346.2017.1342899","volume":"2","author":"Z He","year":"2017","unstructured":"He Z, Zhou J. Can zero-markup policy for drug sales in public hospitals resolve the problem of \u2018seeing a doctor is too expensive\u2019 in China? A case study of four municipal general tertiary hospitals at H City in Z Province. J Chin Gov. 2017;2(3):329\u201342.","journal-title":"J CHIN GOV"},{"key":"15065_CR11","unstructured":"Wang Z. Evaluating the impact of national volume-based procurement: evidence from China. MPRA Paper. 2024."},{"key":"15065_CR12","doi-asserted-by":"publisher","first-page":"1402581","DOI":"10.3389\/fpubh.2024.1402581","volume":"12","author":"J Li","year":"2024","unstructured":"Li J, Zhang X, Wang R, Cao K, Wan L, Ren X, et al. Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises\u2019 R&D investment: a difference-in-differences analysis in China. Front Public Health. 2024;12:1402581.","journal-title":"FRONT PUBLIC HEALTH"},{"issue":"1","key":"15065_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12939-023-02006-1","volume":"22","author":"X Wang","year":"2023","unstructured":"Wang X, He X, Zhang P, Zhang M, Ma R, Dai R, et al. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis. Int J Equity Health. 2023;22(1):200.","journal-title":"INT J EQUITY HEALTH"},{"key":"15065_CR14","doi-asserted-by":"crossref","unstructured":"Yuan J, Lu ZK, Xiong X, Jiang B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Specialist Journals. 2021;(9).","DOI":"10.1136\/bmjgh-2021-005519"},{"issue":"1","key":"15065_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcpt.13551","volume":"47","author":"T Lan","year":"2022","unstructured":"Lan T, Guan L, Pang X, Li X, Yu Q. Impact of the National Centralized Drug Procurement Policy (4\u2009+\u20097 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series. J Clin Pharm Ther. 2022;47(1):104\u201311.","journal-title":"J CLIN PHARM THER"},{"issue":"1","key":"15065_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1186\/s12913-021-07143-3","volume":"21","author":"Y Yang","year":"2021","unstructured":"Yang Y, Tong R, Yin S, Mao L, Xu L, Hao S, et al. The impact of 4\u2009+\u20097 volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis. BMC Health Serv Res. 2021;21(1):1275.","journal-title":"BMC HEALTH SERV RES"},{"key":"15065_CR17","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.34172\/ijhpm.2023.7724","volume":"12","author":"B Zhao","year":"2023","unstructured":"Zhao B, Wu J. Impact of China\u2019s National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin. Int J Health Policy. 2023;12:7724.","journal-title":"INT J HEALTH POLICY"},{"issue":"6","key":"15065_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.clinthera.2009.05.021","volume":"31","author":"I Al-Abbadi","year":"2009","unstructured":"Al-Abbadi I, Qawwas A, Jaafreh M, Abosamen T, Saket M. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan. Clin Ther. 2009;31(6):1335\u201344.","journal-title":"CLIN THER"},{"issue":"1","key":"15065_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healthpol.2012.08.016","volume":"109","author":"S Vandoros","year":"2013","unstructured":"Vandoros S, Stargardt T. Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy. 2013;109(1):1\u20136.","journal-title":"Health Policy"},{"issue":"2","key":"15065_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0020731421997094","volume":"51","author":"MA Rodwin","year":"2021","unstructured":"Rodwin MA. How the United Kingdom controls pharmaceutical prices and spending: learning from its experience. Int J Health Serv. 2021;51(2):229\u201337.","journal-title":"INT J HEALTH SERV"},{"issue":"5","key":"15065_CR21","first-page":"429","volume":"26","author":"F Sigulem","year":"2009","unstructured":"Sigulem F, Zucchi P. E-procurement in the Brazilian healthcare system: the impact of joint drug purchases by a hospital network. Rev Panam Salud Publ. 2009;26(5):429\u201334.","journal-title":"REV PANAM SALUD PUBL"},{"key":"15065_CR22","doi-asserted-by":"crossref","unstructured":"Yuan J, Li M, Jiang X, Lu ZK. National volume-based procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond. BMJ Glob Health. 2024;9(1).","DOI":"10.1136\/bmjgh-2023-014489"},{"key":"15065_CR23","unstructured":"National Healthcare Security Administration: The state council regular policy briefing: progress on the deepen reform of centralized procurement of drug and high value medical consumables. April 7. 2025; 2022. http:\/\/www.nhsa.gov.cn\/art\/2022\/2\/11\/art_14_7835.html."},{"issue":"5","key":"15065_CR24","first-page":"645","volume":"125","author":"A Kotwani","year":"2007","unstructured":"Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, et al. Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res. 2007;125(5):645\u201354.","journal-title":"INDIAN J MED RES"},{"key":"15065_CR25","unstructured":"Kanavos P, Seeley E, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium. Enterp Ind Eur Comm. 2009."},{"key":"15065_CR26","doi-asserted-by":"publisher","first-page":"1233491","DOI":"10.3389\/fphar.2023.1233491","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xu Q, Peng J, Zhang X, Chen L, Wu Y, et al. Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement. Front Pharmacol. 2023;14:1233491.","journal-title":"FRONT PHARMACOL"},{"issue":"7","key":"15065_CR27","doi-asserted-by":"publisher","first-page":"e064199","DOI":"10.1136\/bmjopen-2022-064199","volume":"13","author":"X Wang","year":"2023","unstructured":"Wang X, Huang H, Sun Y, Zhu Z, Jiang B, Yang L. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study. BMJ Open. 2023;13(7):e064199.","journal-title":"BMJ OPEN"},{"issue":"1","key":"15065_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12913-021-06698-5","volume":"21","author":"Y Yang","year":"2021","unstructured":"Yang Y, Chen L, Ke X, Mao Z, Zheng B. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018\u20132019: an interrupted time-series analysis. BMC Health Serv Res. 2021;21(1):668.","journal-title":"BMC HEALTH SERV RES"},{"key":"15065_CR29","doi-asserted-by":"publisher","first-page":"842944","DOI":"10.3389\/fphar.2022.842944","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Lu ZK, Xiong X, Lee TY, Huang H, Jiang B. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus. Front Pharmacol. 2022;13:842944.","journal-title":"FRONT PHARMACOL"},{"issue":"5","key":"15065_CR30","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/hpm.3803","volume":"39","author":"Q Chang","year":"2024","unstructured":"Chang Q, Tian Y, Gao L, Xia N. Challenges and countermeasures for China\u2019s centralised volume-based procurement policy in healthcare. Int J Health Plan M. 2024;39(5):1330\u201349.","journal-title":"INT J HEALTH PLAN M"},{"key":"15065_CR31","doi-asserted-by":"publisher","first-page":"1386533","DOI":"10.3389\/fphar.2024.1386533","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu Y, Mao Z, Mao J, Jin Y. The impact of Chinese volume-based procurement on pharmaceutical market concentration. Front Pharmacol. 2024;15:1386533.","journal-title":"FRONT PHARMACOL"},{"issue":"1","key":"15065_CR32","first-page":"78","volume":"60","author":"C Anghelache","year":"2012","unstructured":"Anghelache C, Marinescu RT, Gheorghe M, Bichir V, Nan S. The laspeyres and paasche indices used in economic and financial analysis. Romanian Stat Rev Supplement. 2012;60(1):78\u201383.","journal-title":"Romanian Stat Rev Supplement"},{"key":"15065_CR33","doi-asserted-by":"crossref","unstructured":"Eichhorn W, Voeller J. Theory of the price index: fisher\u2019s test approach and generalizations. 1977.","DOI":"10.1007\/978-3-642-45492-9"},{"issue":"1","key":"15065_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1186\/s12913-023-09774-0","volume":"23","author":"L Li","year":"2023","unstructured":"Li L, Liu B. Spatial price differences of medical services: evidence from the Yangtze River Delta in China. BMC Health Serv Res. 2023;23(1):761.","journal-title":"BMC HEALTH SERV RES"},{"key":"15065_CR35","doi-asserted-by":"crossref","unstructured":"Diewert WE. Weighted country product dummy variable regressions, and index number formulae. Rev Income Wealth. 2010;51.","DOI":"10.1111\/j.1475-4991.2005.00168.x"},{"key":"15065_CR36","doi-asserted-by":"publisher","first-page":"944540","DOI":"10.3389\/fphar.2022.944540","volume":"13","author":"H Long","year":"2022","unstructured":"Long H, Yang Y, Geng X, Mao Z, Mao Z. Changing characteristics of pharmaceutical prices in China under centralized procurement policy: a multi-intervention interrupted time series. Front Pharmacol. 2022;13:944540.","journal-title":"FRONT PHARMACOL"},{"issue":"1","key":"15065_CR37","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1186\/s12889-021-11882-7","volume":"21","author":"N Wang","year":"2021","unstructured":"Wang N, Yang Y, Xu L, Mao Z, Cui D. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis. BMC Public Health. 2021;21(1):1883.","journal-title":"BMC Public Health"},{"issue":"8","key":"15065_CR38","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/cid\/cix1001","volume":"66","author":"HC Turner","year":"2018","unstructured":"Turner HC, Toor J, Hollingsworth TD, Anderson RM. Economic evaluations of mass drug administration: the importance of economies of scale and scope. Clin Infect Dis. 2018;66(8):1298\u2013303.","journal-title":"CLIN INFECT DIS"},{"key":"15065_CR39","doi-asserted-by":"crossref","unstructured":"Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of Shenzhen, China. Int J Env Res Pub He. 2020;17(24).","DOI":"10.3390\/ijerph17249415"},{"key":"15065_CR40","doi-asserted-by":"publisher","first-page":"923209","DOI":"10.3389\/fphar.2022.923209","volume":"13","author":"J Lu","year":"2022","unstructured":"Lu J, Long H, Shen Y, Wang J, Geng X, Yang Y, et al. The change of drug utilization in China\u2019s public healthcare institutions under the 4\u2009+\u20097 centralized drug procurement policy: Evidence from a natural experiment in China. Front Pharmacol. 2022;13:923209.","journal-title":"FRONT PHARMACOL"},{"key":"15065_CR41","doi-asserted-by":"crossref","unstructured":"Levaggi L, Levaggi R, White LJ. Spatial competition models in health care markets: a review. Rev Ind Organ. 2024;65(3).","DOI":"10.1007\/s11151-024-09978-6"},{"key":"15065_CR42","volume-title":"Making Medicines Affordable: A National Imperative","author":"HAM Division","year":"2017","unstructured":"National Academies of Sciences EAM, Division HAM, Services BOHC, Therapies COEP. Making medicines affordable: a national imperative. Washington (DC): National Academies Press (US); 2017."},{"key":"15065_CR43","doi-asserted-by":"crossref","unstructured":"Diamond R, Moretti E. Where is standard of living the highest? Local prices and the geography of consumption. Nat Bureau Econ Res. 2021.","DOI":"10.3386\/w29533"},{"key":"15065_CR44","doi-asserted-by":"publisher","first-page":"113247","DOI":"10.1016\/j.socscimed.2020.113247","volume":"263","author":"W Shi","year":"2020","unstructured":"Shi W, Wouters OJ, Liu G, Mossialos E, Yang X. Association between provincial income levels and drug prices in China over the period 2010\u20132017. Soc Sci Med. 2020;263:113247.","journal-title":"SOC SCI MED"},{"issue":"6","key":"15065_CR45","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.12677\/SD.2022.126184","volume":"12","author":"S Deng","year":"2022","unstructured":"Deng S. The current situation, problems and solutions of the basic medical insurance fund in China. Sustain Dev. 2022;12(6):1599\u2013610.","journal-title":"SUSTAIN DEV"},{"key":"15065_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/CEOR.S140063","volume":"9","author":"D George","year":"2017","unstructured":"George D, Ira J, Carol K, Robert P, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoeconomics Outcomes Res Ceor. 2017;9:573\u201384.","journal-title":"Clinicoeconomics Outcomes Res Ceor"},{"key":"15065_CR47","first-page":"469580221146041","volume":"60","author":"L Chen","year":"2023","unstructured":"Chen L, Chen T, Lan T, Chen C, Pan J. The contributions of population distribution, healthcare resourcing, and transportation infrastructure to spatial accessibility of health care. Inquiry-J Health Car. 2023;60:469580221146041.","journal-title":"INQUIRY-J HEALTH CAR"},{"issue":"07","key":"15065_CR48","first-page":"769","volume":"34","author":"D Zhou","year":"2023","unstructured":"Zhou D, Kuai L, Xu D, Tian L. Analysis of the shortage of drugs in national centralized volume-based procurement and countermeasures and suggestions. China Pharm. 2023;34(07):769\u201373.","journal-title":"China Pharm"},{"key":"15065_CR49","doi-asserted-by":"publisher","first-page":"621307","DOI":"10.3389\/fphar.2021.621307","volume":"12","author":"M Zhao","year":"2021","unstructured":"Zhao M, Gillani AH, Ji D, Feng Z, Fang Y, Yang C. Impact of the low-price medicine policy on medicine supply in China: an interrupted time-series analysis. Front Pharmacol. 2021;12:621307.","journal-title":"FRONT PHARMACOL"},{"key":"15065_CR50","doi-asserted-by":"publisher","first-page":"1185356","DOI":"10.3389\/fpubh.2023.1185356","volume":"11","author":"S Hu","year":"2023","unstructured":"Hu S, Zhang J, Li J, Zhang J, Pan M, Xiang C, et al. The impact of drug shortages on drug prices: evidence from China. Front Public Health. 2023;11:1185356.","journal-title":"FRONT PUBLIC HEALTH"},{"key":"15065_CR51","unstructured":"Tang Y, Ye H, Jiao J, Yang S. Centralized drug procurement, volume-for-priceand pharmaceutical enterprise innovation: How to achieve a win-win for pharmaceutical burden reduction andinnovative development of pharmaceutical enterprises? China Soft Sci. 2023(12):123\u201333."},{"issue":"7","key":"15065_CR52","first-page":"9","volume":"30","author":"I Hernandez","year":"2024","unstructured":"Hernandez I, Sullivan CSD, Hansen RN, Fendrick AM. Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them. J Manag Care Spec Ph. 2024;30(7):9.","journal-title":"J MANAG CARE SPEC PH"},{"key":"15065_CR53","unstructured":"National health commission of the People\u2019s Republic of China: policy interpretation: opinions on reforming and improving the collaborative management mechanism for essential drugs at the primary care level and expanding the variety of essential drugs. April 7. 2025; 2024. https:\/\/www.gov.cn\/zhengce\/zhengceku\/202411\/content_6988935.htm."},{"key":"15065_CR54","doi-asserted-by":"crossref","unstructured":"Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, et al. Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol. 2021;12:693426.","DOI":"10.3389\/fphar.2021.693426"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15065-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15065-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15065-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:31:30Z","timestamp":1790807490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-15065-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15065"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15065-1","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study used anonymized administrative procurement data and did not involve individual-level human subject data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1339"}}